Afra Darvishi

Afra Darvishi

Auto-generated profile, based on publicly available information

Afra Darvishi

Student research committee, Tabriz University of Medical Sciences, Tabriz, 5166614756, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
SHSakineh Hajebrahimi
Sakineh Hajebrahimi
ADAfra Darvishi
Afra Darvishi
RHReyhaneh HajEbrahimi
Reyhaneh HajEbrahimi
NANazli Asadi
Nazli Asadi
ZSZahra Jafari Shendi
Zahra Jafari Shendi
HSHanieh Salehi-Pourmehr
Hanieh Salehi-Pourmehr

15 October 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
ADAfra Darvishi
Afra Darvishi
AAAmirhosein Dadashzadeh Asl
Amirhosein Dadashzadeh Asl
PGPouya Golshaniniya
Pouya Golshaniniya
AAAli Alipour
Ali Alipour
ANAmirreza Naseri
Amirreza Naseri
HSHanieh Salehi-Pourmehr
Hanieh Salehi-Pourmehr
Early detection of gastric cancer (GC) is crucial for lowering the mortality risk and health burden. Since various biomarkers have been studied for the early diagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or predicting the risk. Following the PRISMA statement and Joanna Briggs Institute (JBI) Manual, PubMed, Scopus, and Web of Science were searched before August 31, 2023. English-language systematic reviews that assessed the association between serum markers and the presence of and/or predicting the risk of GC with or without meta-analyses were included in this umbrella review. The chosen reviews assessed serum markers in GC, and the quality assessment was conducted by the JBI critical appraisal tool for systematic reviews. From 1441 records that remained after removing the duplicates, only seven were selected. The investigated serum markers in the studies included SOD activity, selenium, adiponectin dickkopf-1, pepsinogens, and autoantibodies. The bias risk in most of the included reviews was appropriately low. Overall, the SOD activity, circulating adiponectin, and selenium are suggested to be lower in patients with GC. Serum dickkopf-1 and serum pepsinogen are also proposed as potential biomarkers for GC. Considering the great heterogeneity between the studies, the possibility of publication bias, and the limited number of the included studies further investigation is required. The explained serum biomarkers could be helpful for diagnosis and predicting GC; however, further well-designed large-scale investigation is needed to ensure their clinical applications.

14 May 2026 in Scientific Reports
Verified
Journal Article
Open access
AAAli Alipour
Ali Alipour
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
ADAfra Darvishi
Afra Darvishi
SPShahriar Parvaneh
Shahriar Parvaneh
MTMalihe Talebi
Malihe Talebi
ANAmirreza Naseri
Amirreza Naseri
Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.

26 May 2025 in Brain and Behavior
Verified
Journal Article
Open access
PSParsa Saberian
Parsa Saberian
ADAfra Darvishi
Afra Darvishi
DKDelnia Khezragha
Delnia Khezragha
MFMoojan Forouzandegan
Moojan Forouzandegan
MFMohammad‐Erfan Farhadieh
Mohammad‐Erfan Farhadieh
SSShayan Shakeri
Shayan Shakeri
Purpose: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.Method: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).Findings: The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.Conclusion: Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.

8 November 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
ADAfra Darvishi
Afra Darvishi
SPSina Pakkhesal
Sina Pakkhesal
AAAli Alipour
Ali Alipour
ZSZahra Jafari Shendi
Zahra Jafari Shendi
RHReyhaneh HajEbrahimi
Reyhaneh HajEbrahimi
ANAmirreza Naseri
Amirreza Naseri

29 September 2025 in Biomedical Research Bulletin
Verified
Journal Article
Open access
PDF file
AAAli Alipour
Ali Alipour
ADAfra Darvishi
Afra Darvishi
Neurodegenerative diseases, such as (but not limited to) Alzheimer’s disease and Parkinson’s disease, are a serious global health problem. Considering that the current treatments are primarily focused on symptom relief, it is necessary to find novel therapeutic approaches, including target therapies. Sharks have a special biochemical potential, and various neuroprotective agents can be derived from these animals. This review aims to evaluate and summarize the data available on shark-derived compounds in the case of neurodegeneration, explaining the molecular signatures and insights for novel therapies. Squalamine, trodusquemine, and single domain antibodies are the major products discussed in this paper. This review study further provides molecular pathways and clinical and animal data due to date, suggesting promising insights into more investigations in this field.